These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 39208833

  • 1. Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
    Brault A, Pontais I, Enouf V, Debeuret C, Bloch E, Paireau J, Rameix-Welti MA, White M, Baudemont G, Lina B, Parent du Châtelet I, Casalegno JS, Vaux S, Cauchemez S.
    Lancet Child Adolesc Health; 2024 Oct; 8(10):721-729. PubMed ID: 39208833
    [Abstract] [Full Text] [Related]

  • 2. Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France.
    Carbajal R, Boelle PY, Pham A, Chazette Y, Schellenberger M, Weil C, Colas AS, Lecarpentier T, Schnuriger A, Guedj R, Lorrot M, Corvol H, Enault M.
    Lancet Child Adolesc Health; 2024 Oct; 8(10):730-739. PubMed ID: 39208832
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).
    Coma E, Martinez-Marcos M, Hermosilla E, Mendioroz J, Reñé A, Fina F, Perramon-Malavez A, Prats C, Cereza G, Ciruela P, Pineda V, Antón A, Ricós-Furió G, Soriano-Arandes A, Cabezas C.
    Arch Dis Child; 2024 Aug 16; 109(9):736-741. PubMed ID: 38857952
    [Abstract] [Full Text] [Related]

  • 9. Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study.
    López-Lacort M, Corberán-Vallet A, Santonja FJ, Muñoz-Quiles C, Díez-Domingo J, Orrico-Sánchez A.
    J Infect Public Health; 2024 Aug 16; 17(8):102492. PubMed ID: 39002465
    [Abstract] [Full Text] [Related]

  • 10. Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments.
    Andina Martínez D, Claret Teruel G, Gijón Mediavilla M, Cámara Otegui A, Baños López L, de Miguel Lavisier B, Ferrero García-Loygorri C, Sánchez Tatay V, Pavlovic Nesic S, Clerigué Arrieta N, Gimeno-Hernández Garza V, Guerra Diez JL, Ranera Málaga A, Escalada Pellitero S, Barrueco Ramos C, Alonso-Cadenas JA, Impact of universal Respiratory Syncytial Virus prophylaxis in Spain Working Group.
    Pediatrics; 2024 Oct 01; 154(4):. PubMed ID: 39257372
    [Abstract] [Full Text] [Related]

  • 11. Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.
    Gil-Prieto R, Pérez JJ, Drago G, Kieffer A, Roïz J, Kazmierska P, Sardesai A, de Boisvilliers S, López-Belmonte JL, Beuvelet M, Aldean JA.
    BMC Infect Dis; 2024 Sep 06; 24(1):924. PubMed ID: 39242545
    [Abstract] [Full Text] [Related]

  • 12. The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study.
    Barbas Del Buey JF, Íñigo Martínez J, Gutiérrez Rodríguez MÁ, Alonso García M, Sánchez-Gómez A, Lasheras Carbajo MD, Jiménez Bueno S, Esteban Vasallo MD, López Zambrano MA, Calvo Rey C, Sanchez Luna M, Molina Olivas M, Arce Arnáez MA.
    Front Public Health; 2024 Sep 06; 12():1441786. PubMed ID: 39220460
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, Halasa NB, Staat MA, Weinberg GA, Selvarangan R, Michaels MG, Sahni LC, Klein EJ, Stewart LS, Schlaudecker EP, Szilagyi PG, Schuster JE, Goldstein L, Musa S, Piedra PA, Zerr DM, Betters KA, Rohlfs C, Albertin C, Banerjee D, McKeever ER, Kalman C, Clopper BR, New Vaccine Surveillance Network Product Effectiveness Collaborators, McMorrow ML, Dawood FS.
    MMWR Morb Mortal Wkly Rep; 2024 Mar 07; 73(9):209-214. PubMed ID: 38457312
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, Baca Cots M, Domachowske JB, Garcia-Garcia ML, Grantina I, Nguyen KA, Zar HJ, Berglind A, Cummings C, Griffin MP, Takas T, Yuan Y, Wählby Hamrén U, Leach A, Villafana T.
    Lancet Child Adolesc Health; 2023 Mar 07; 7(3):180-189. PubMed ID: 36634694
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
    Gebretekle GB, Yeung MW, Ximenes R, Cernat A, Simmons AE, Killikelly A, Siu W, Rafferty E, Brousseau N, Tunis M, Tuite AR.
    Vaccine; 2024 Aug 30; 42(21):126164. PubMed ID: 39079810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.